cagrilintide + semaglutide Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has well-established weight-loss benefits. Cagrilintide, a long-acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential benefit The combination of semaglutide and

Assessment of biochemical hyperandrogenism would be useful in establishing the diagnosis of PCOS and/or phenotype where clinical signs of hyperandrogenism (in particular hirsutism) would not be unclear or absent

Ongoing trialsSOUL, FLOW, SELECT, and SURPASS-CVOTwill clarify the role of semaglutide in heart failure and advanced CKD and determine whether dual GLP-1/GIP agonism surpasses single-receptor strategies

Before discontinuing treatment, individuals treating obesity lost an average of 8.4% of body weight, while those treating type 2 diabetes lost an average of 4.4% of body weight

Wegovy is a once-weekly subcutaneous injection at a higher dose (2.4 mg) approved for chronic weight management and cardiovascular risk reduction

Treatment with vildagliptin over a longer period of time could also confirm an increased -cell function in humans as a result of improved sensitivity of cells to glucose (140, 141)

There is some evidence to suggest that glutathione may be beneficial for people with Parkinsons disease